Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant virus encoding one or more heterologous proteins...
Patent
1997-01-30
2000-01-11
Mosher, Mary E.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant virus encoding one or more heterologous proteins...
4242291, 4242141, 424816, 424 932, 435 693, 4353201, 536 2372, 536 241, A61K 3912, A61K 39245
Patent
active
060132612
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD OF THE INVENTION
The present invention relates to a novel recombinant virus which can express an exogenous gene in an animal cell or in an animal body and can persistently infect even in the presence of a maternal antibody to continue antigen stimulation for a long period of time while escaping from challenge of the host immune system, thereby providing a vaccine which is effective even for conventional animals having a maternal antibody. The present invention also relates to a polyvalent live vaccine for animals using said recombinant virus. The present invention further relates to a recombinant virus vector which can be used as a drug delivery system (DDS) for production of physiologically active substances such as hormones or cytokines within the living body.
BACKGROUND OF THE INVENTION
Virus vector has widely been studied for efficiency of vaccination and for use as a gene introduction system into the living body. Particularly in the poultry industry, a study for application of poxviruses, especially fowlpox virus, has made a rapid progress. Under the circumstances, in order to develop a more efficient vector, the present inventors have investigated to make a vector from Marek's disease virus type 1 (hereinafter also referred to as "MDV1"), a kind of avian herpes viruses, and have reported many results thereof. For example, the present inventors have investigated more than 20 sites on the MDV1 genome, and as a result, have identified US10 gene as an insertion site for an exogenous gene which can stably retain an exogenous gene but does not impair the vaccine effects against Marek's disease [Japanese patent application No. 4-205933 (Japanese patent publication No. 6-22757); 4th International Symposium on Marek's Disease (1992), Amsterdam; Vaccine 1994 Vol. 12, 953-957]. A recombinant virus which incorporates F protein gene of Newcastle disease virus into the US10 gene exhibited sufficient effects as a vaccine in SPF chickens, said effects being persistent over at least 24 weeks after inoculation (4th International Symposium on Marek's Disease (1992), Amsterdam). This recombinant virus has been proved to show protective effects against both Marek's disease and Newcastle disease even in chickens having maternal antibodies but the protective effects were somewhat lowered than in SPF chickens. That is, this recombinant virus showed efficiently 100% protective effects against Newcastle disease in SPF chickens whereas it showed somewhat lowered effects, i.e. 70 to 90% level, in field chickens having maternal antibodies (Current Developments in the Molecular Biology of Marek's Disease Virus Workshop, 1995, Florida). Such a decrease in the effects was supposedly due to suppression of in vivo growth of the recombinant virus by maternal antibodies against Newcastle disease and Marek's disease when field chickens are immunized with the recombinant virus.
DISCLOSURE OF THE INVENTION
As mentioned above, when a live vaccine comprising a recombinant virus is inoculated into an animal having maternal antibodies, a problem arises that said virus is eliminated or viral growth is inhibited by the host immune system such as maternal antibodies. Thus, an improved recombinant virus is desired which retains the properties of a live vaccine and can continuously provide antigen stimulation for a long period of time while escaping from the challenge of the immune system.
In order to solve the above-mentioned problem, the present inventors have noted promoters derived from MDV1 and have cloned several putative promoter genes from Marek's disease virus (hereinafter also referred to as "MDV") genome. Using these promoter genes, the present inventors have conducted an experiment for expression of an exogenous gene in a recombinant virus comprising said genes. As a result, it was found, that among several promoter genes which the present inventors have cloned, a promoter from glycoprotein B (hereinafter referred to as "gB") gene, a gene homologous to herpes simplex virus gB gene, exhibited particularly excellen
REFERENCES:
patent: 5171677 (1992-12-01), Sakaguchi et al.
patent: 5558860 (1996-09-01), Ross et al.
patent: 5659153 (1997-08-01), Ishikawa et al.
Ross et al. (1) J. Gen. Virol. 74: 371-377, 1993.
Haynes et al. Science 260: 1279-1286, 1993.
"Proceedings 19th World's Poultry Congress", vol. 1, pp. 332-335, Amsterd Sep. 19-24, 1992.
Sakaguchi et al., "Construction of Recombinant Marek's Disease Virus Type 1 (MDV1) Expressing the Escherichia coli LacZ Gene as a Possible Live Vaccine Vector: The US10 Gene of MDV1 as a Stable Insertion Site", Vaccine, vol. 12, No. 10, pp. 953-957, 1994.
Sonoda et al., "Protection of Convential Chickens Against Marek's Disease and Newcastle Disease by MDV1 Recombinants", Current Developments in the Molecular Biology of Marek's Disease Virus Workshop, p. 23, 1995.
Eberle et al., "Topological Distribution of Virus-Specific and Cross-Reactive Antigenic Determinants on the gB Glycoprotein of the Herpes Simplex Viruses", Journal of Medical Virology, vol. 27, pp. 309-316, 1989.
Desrosiers et al., "Synthesis of Bovine Growth Hormone in Primates by Using a Herpesvirus Vector", Molecular and Cellular Biology, vol. 5, No. 10, pp. 2796-2803, Oct. 1985.
Glazenburg et al., "Construction and Properties of Pseudorabies Virus Recombinants with Altered Control of Immediate-Early Gene Expression", Journal of Virology, vol. 69, No. 1, pp. 189-197, Jan., 1995.
Federoff et al., "Expression of Nerve Growth Factor In Vivo From a Defective Herpes Simplex Virus 1 Vector Prevents Effects of Axotomy on Sympathetic Ganglia", Proc. Natl. Acad. Sci. USA, vol. 89, pp. 1636-1640, Mar. 1992.
Bzik et al., "The Nucleotide Sequence of the gB Glycoprotein Gene of HSV-2 and Comparison with the Corresponding Gene of HSV-1", Virology 155, pp. 322-333, 1986.
Lowe et al., "Varicella-Zoster Virus as a Live Vector for the Expression of Foreign Genes", Proc. Natl. Acad. Sci. USA, vol. 84, pp. 3896-3900, Jun., 1987.
Telford et al., "The DNA Sequence of Equine Herpesvirus-1", Virology, 189, pp. 304-316, 1992.
Whitbeck et al., "Comparison of the Bovine Herpesvirus 1 gI Gene and the Herpes Simplex Type 1 gB Gene", Journal of Virology, vol. 62, No. 9, pp. 3319-3327, Sep., 1988.
Hammerschmidt et al., "Conservation of a Gene Cluster Including Glycoprotein B in Bovine Herpesvirus Type 2 (BHV-2) and Herpes Simplex Virus Type 1 (HSV-1)", Virology 165, pp. 388-405, 1988.
Spaete et al., "Insertion and Deletion Mutagensis of the Human Cytomegalovirus Genome", Proc. Natl. Acad. Sci. USA, vol. 84, pp. 7213-7217, Oct. 1987.
Sondermeijer et al., "Avian Herpesvirus as a Live Viral Vector for the Expression of Heterologous Antigens", Vaccine, vol. 11, issue 3, pp. 349-358, 1993.
Chee et al., "Analysis of the Protein-Coding Content of the Sequence of Human Cytomegalovirus Strain AD169", Current Topics in Microbiology 154 and Immunlogy, vol. 154, pp. 126-169, 1990.
Ellinger et al., "The Glycoprotein B Homologue of Human Herpesvirus 6", Journal of General Virology, vol. 74, pp. 495-500, 1993.
Davison et al., "Genetic Relations Between Varicella-Zoster Virus and Epstein-Barr Virus", J. Gen. Virol., vol. 68, pp. 1067-1079, 1987.
Sakaguchi et al., "Sequence Determination and Genetic Content of an 8.9-kb Restriction Fragment in the Short Unique Region and the Internal Inverted Repeat of Marek's Disease Virus Type 1 DNA", Virus Genes 6:4, pp. 365-378, 1992.
Buckmaster et al., "Gene Sequence and Mapping Data From Marek's Disease Virus and Herpesvirus of Turkeys: Implications For Herpesvirus Classification", J. Gen. Virol., vol. 69, pp. 2033-2042, 1988.
Ross et al., "Nucleotide Sequence and Characterization of the Marek's Disease Virus and Homologue of Glycoprotein B of Herpes Simplex Virus", J. Gen. Virol., vol. 70, pp. 1789-1804, 1989.
Umino et al., "Protective Effect of Monoclonal Antibodies to Newcastle Disease Virus in Passive Immunization", Journal of General Virology, vol. 71, pp. 1199-1203, 1990.
"119th Japanese Society of Veterinary Science", p. 116, Mar. 31-Apr. 2, 1995.
"42nd Japan Virology
Hamada Fukusaburo
Matsuo Kazuo
Sakaguchi Masashi
Sonoda Kengo
Juridical Foundation The Chemo-Sero-Therapeutic Research Institu
Mosher Mary E.
Salimi Ali R.
LandOfFree
Recombinant Marek's disease virus (MDV) and vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant Marek's disease virus (MDV) and vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant Marek's disease virus (MDV) and vaccine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1459848